NCT06170970View on ClinicalTrials.gov

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

March 1, 2027

Conditions
Multiple SclerosisMultiple Sclerosis Fatigue
Interventions
DRUG

Solriamfetol

solriamfetol 75 mg daily for 3 days and will increase the dose to 150 mg daily starting on day 4 of the treatment period (total of four weeks)

DRUG

Placebo

Four weeks of oral placebo

Trial Locations (1)

21287

RECRUITING

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Axsome Therapeutics, Inc.
All Listed Sponsors
collaborator

National Multiple Sclerosis Society

OTHER

collaborator

Axsome Therapeutics, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER